How it works:
Inhibits tumour cell proliferation
Blocks angiogenesis (formation of blood vessels supplying the tumour)
Slows disease progression
Suitable for targeted cancer therapy
Recommended for:
Hepatocellular carcinoma (liver cancer)
Renal cell carcinoma (kidney cancer)
Radioiodine-refractory differentiated thyroid cancer
Used for advanced hepatocellular carcinoma, advanced renal cell carcinoma and differentiated thyroid cancer unresponsive to radioactive iodine therapy
Taken orally, typically twice daily, on an empty stomach or two hours after meals. Dosage is determined individually by the physician depending on patient condition and cancer stage.
Contraindications
Hypersensitivity to sorafenib
Severe liver impairment
Pregnancy and lactation
Children under 18 years
Severe cardiovascular conditions
Side Effects
Diarrhoea, nausea, loss of appetite
Fatigue
Skin rash, hand-foot skin reaction
Hypertension
Thrombocytopenia, anaemia